1. SEROTONIN-DOPAMINE INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM
1. Serotonin-Dopamine Interaction: an overview
E. Esposito, V. Di Matteo and G. Di Giovanni (Santa Maria Imbaro, Chieti and Palermo, Italy)
2. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies
V. Di Matteo, G. Di Giovanni, M. Pierucci and E. Esposito (Santa Maria Imbaro, Chieti and Palermo, Italy)
3. Serotonin-Dopamine Interaction: electrophysiological evidence
G. Di Giovanni, V. Di Matteo, M. Pierucci and E. Esposito (Palermo and Santa Maria Imbaro, Chieti, Italy
4. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders
U.M. D’Souza and I.W. Craig (London, UK)
2. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA
5. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment
J. de Almeida, J.M. Palacios and G. Mengod (Barcelona, Spain)
6. Alterations of dopamine and serotonin transmission in schizophrenia
G. Remington (Toronto, ON, Canada)
7. Serotonin and dopamine interactions in psychosis prevention
N.M. Richtand and R.K. McNamara (Cincinnati, OH, USA)
8. Role of serotonin and dopamine receptor binding in antipsychotic efficacy
N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski and R.K. McNamara (Cincinnati, OH, USA)
9. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
H.Y. Meltzer and M. Huang (Nashville, TN, USA)
10. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
T. Kuroki, N. Nagao and T. Nakahara (Kanzaki, Japan)
11. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders
M.D. Wood and P.W. Wren (Harlow, UK)
3. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION
12. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease
K.A. Michelsen, J. Prickaerts and H.W.M. Steinbusch (Maastricht, The Netherlands)
13. Dynamics of the dopaminergic system as a key component to the understanding of depression
G. Yadid and A. Friedman (Ramat-Gan, Israel)
14. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression
K.A. Berg, J.A. Harvey, U. Spampinato and W.P. Clarke (San Antonio, TX, Philadelphia, PA, USA and Bordeaux, France)
15. The role of dopamine and serotonin in suicidal behaviour and aggression
E. Ryding, M. Lindström and L.Träskman-Bendz (Stockholm, Sweden)
4. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION
16. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse
M.J. Bubar and K.A. Cunningham (Galveston, TX, USA)
17. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour
R.J. Carey, J.P. Huston and C.P. Müller (Dusseldorf, Germany and London, UK)
18. Serotonin receptors as potential targets for modulation of nicotine use and dependence
P.J. Fletcher, A. Dzung Lê and G.A. Higgins (Toronto, ON, Canada)
19. Dopamine/Serotonin releasers as medications for stimulant addictions
R.B. Rothman, B.E. Blough and M.H. Baumann (Baltimore, MD and Triangle Park, NC, USA)
20. PTEN-5-HT2C coupling: A new target for treating drug addiction
J.-C. Maillet, Y. Zhang, X. Li, X. Zhang (Ottawa, ON, Canada)
5. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS
21. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders
V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno and G. Di Giovanni (Santa Maria Imbaro, Chieti, and Palermo, Italy)
22. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias
M. Carta, T. Carlsson, A. Muňoz, D. Kirik and A. Björklund (Lund, Sweden)
23. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy
S.H. Fox, R. Chuang and J.M. Brotchie (Toronto, ON, Canada)
24. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome